Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma

Nowadays, glioblastoma (GBM) was the most common and lethal form of primary intracranial tumor. Despite standard-of-care therapy, GBM still exhibited a poor prognosis with 5-years survival rate less than 5%. Recent years, adoptive CAR-T therapy came to be a novel immunotherapy in treating malignant tumors. Great progress has been made by CD19 targeted CAR-T cells against refractory B cell cancers. Recent studies also reported about the clinical potential of CAR-T therapy targeting IL13Ra2 and EGFRvIII in treating GBM. 1 , 2 However, limited numbers of therapeutic targets in GBM may preclude it from progress and being popularized.